TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05086692: A Beta-only IL-2 ImmunoTherapY Study

Sponsor: Medicenna Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT05086692 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05086692 Rescue Dossier →